MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces a strategic research collaboration with Johns Hopkins University (JHU) to develop unique Chimeric Antigen Receptor (CAR) T-cell therapies, which harness patients’ own immune systems to combat cancers. MaxCyte’s unique approach to CAR cell therapy allows targeting of solid tumor cancers by enabling control over the on-target, off-tumor toxicity, which limits other CAR therapies to hematological cancers. MaxCyte achieves this by introducing the CAR construct as…
Tuesday, April 21, 2015 Daily Archives
New Customized Fluid Transfer Service Simplifies the Biopharmaceutical Manufacturing Process
Today’s manufacturers searching to simplify their supply chains and sharpen their production capabilities can benefit from a new fluid transfer service specifically for aseptic biopharmaceutical production. The Thermo Scientific Customized Fluid Transfer Service provides pre-sterilized and ready-to-use consumables tailored for a customer’s facility needs, freeing up the manufacturer’s time to focus on critical operations while optimizing cleanroom usage. This new service – including examples of possible system configurations – will be showcased this week at the INTERPHEX 2015 Conference and…
Single-Use-Bioprocesses – Hype or Future Technology?
Single-use technology have become indispensable in biopharmaceutical manufacturing. Rentschler is one of the first contract manufacturers worldwide to establish a complete single-use facility for the upstream and downstream processes.